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The value of secondary cytoreductive surgery (SCS) for recurrent ovarian cancer is still controversial. The aim of this study was to
clarify candidates for SCS. Between January 1987 and September 2000, we performed SCS in 44 patients with recurrent ovarian
cancer, according to our selection criteria, disease-free interval (DFI) 46 months, performance status o3, no apparent multiple
diseases, age o75years and no progressive disease during preoperative chemotherapy, if undertaken. The variables were investigated
by univariate and multivariate analyses. Of 44 patients, 26 (59.1%) achieved complete removal of all visible tumours at SCS.
Secondary cytoreductive surgery outcome, complete or incomplete resection, was significantly related to overall survival
(P¼0.0019). As for variables determined before SCS, DFI 412 months, no liver metastasis, solitary tumour and tumour size o6cm
were independently associated with favourable overall survival after recurrence in the multivariate analysis. Patients with three or all
four variables (n¼31) had significantly better survival compared with the other patients (n¼13) (47 vs 20 months in median survival,
Po0.0001). In these patients, fairly good median survival (40 months) was obtained even in patients with incomplete resection.
Secondary cytoreductive surgery had a large impact on survival of patients with recurrent ovarian cancer when they had three or all
of the above-mentioned four factors at recurrence. These patients should be considered as ideal candidates for SCS.
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Since Griffiths (Griffiths, 1975) first demonstrated the inverse
relationship between residual tumour size after primary debulking
and survival of ovarian cancer patients in 1975, many investigators
have reproduced and confirmed this observation (Hacker et al,
1983; Vogl et al, 1983; Delgado et al, 1984; Conte et al, 1985; Louie
et al, 1986; Neijt et al, 1987; Hainsworth et al, 1988; Sutton et al,
1989). Thus, the value of debulking of large tumour masses in the
primary surgery of ovarian cancer has been generally accepted,
and primary cytoreductive surgery followed by chemotherapy is
considered to be a standard treatment procedure for patients with
advanced ovarian cancer.
The cytoreduction contributes to removal of the tumour burden
and relief of symptoms caused by tumours or massive ascites. In
addition, the cytoreduction has another important effect on the
sensitivity to postsurgical chemotherapy. By removing bulky
tumours, the decreased growth fractions should increase (Norton
and Simon, 1977) and poorly perfused anoxic cells should
decrease. By reducing the number of cancer cells, the chance for
cancer cells to undergo spontaneous mutations resulting in drug
resistance should decrease (Goldie and Coldman, 1979). All these
effects are believed to enhance the sensitivity to chemotherapy.
Theoretically, the favourable effects of cytoreduction may also
be expected in patients with recurrent ovarian cancer. Recently,
several investigators have reported the significant value of
secondary cytoreductive surgery (SCS) in a subset of patients with
recurrent ovarian cancer (Ja ¨nicke et al, 1992; Eisenkop et al, 1995,
2000; Vaccarello et al, 1995; Cormio et al, 1999; Zang et al, 2000,
2004; Munkarah et al, 2001; Scarabelli et al, 2001; Tay et al, 2002).
The value of complete resection at the time of SCS for highly
selected patients is in consensus in these recent reports. They
reported a considerable number of factors related to good
prognosis including longer disease-free interval (DFI), smaller
size of residual tumour at primary cytoreductive surgery, good
response to first-line chemotherapy, younger age at recurrence and
smaller size of maximum tumour at recurrence. However, there is
limited information regarding the ideal candidates for SCS.
Although only preoperative or intraoperative variables before
starting SCS should be analysed for selection of the candidate,
these variables have been analysed together with SCS outcome in
most previous studies. In addition, the follow-up periods of living
patients were rather short (the median or average follow-up
periods were between 1 and 4 years) (Ja ¨nicke et al, 1992;
Vaccarello et al, 1995; Cormio et al, 1999; Zang et al, 2000, 2004;
Munkarah et al, 2001; Scarabelli et al, 2001) in most of the
previous reports.
Since 1987, we have performed SCS according to our criteria of
patient selection in 44 out of 70 ovarian cancer patients who had
recurrence after DFI. In the present study, the median follow-up
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speriod of living patients is 60 months after the initiation of
treatment, SCS or chemotherapy before SCS, for recurrence. Using
univariate and multivariate analyses of variables before starting
SCS, we planned to clarify the ideal candidates for SCS among
patients with recurrent ovarian cancer.
PATIENTS AND METHODS
Patient selection
Between January 1984 and December 1999, we treated 236 patients
with stage I to IV epithelial ovarian cancer at the Department of
Obstetrics and Gynecology, University of Tokyo Hospital. Our
standard surgical procedures for ovarian cancer consist of total
abdominal hysterectomy, bilateral salpingo-oophorectomy, infra-
colic or total omentectomy, and in advanced cases, debulking of
tumour masses with maximum efforts. Patients with no or small
intraperitoneal residual tumours (less than 2cm in diameter) also
underwent systematic retroperitoneal lymphadenectomy. The
extent of retroperitoneal lymphadenectomy is pelvic lymph nodes
only (1984–1986) or both pelvic and aortic lymph nodes (1987–
1999). All but stage Ia patients underwent at least six cycles of
cisplatin-based chemotherapies following surgery as described
previously (Onda et al, 1998). Of the 236 patients, 204 (86%)
achieved complete clinical remission after primary treatment.
By September 2000, 70 of the 204 (34%) patients had recurrence
and, from January 1987 to September 2000, 44 of the 70 (63%)
patients underwent SCS prior to or following chemotherapy.
Administration of chemotherapy before SCS was decided based on
various clinical factors including short DFI (DFI o12 months) and
poor performance status (PS 3) defined by ECOG (Eastern
Cooperative Oncology Group). Our selection criteria for SCS were
as follows: (1) DFI 46 months, (2) age at recurrence o75 years,
(3) PS 0–2 just before the surgery, (4) absence of apparent
extensive intraperitoneal dissemination or multiple distant metas-
tases and (5) no progressive disease during presurgical che-
motherapy, if undertaken. There were three exceptions to the
above-mentioned criteria for SCS. One patient with DFI o6
months (5 months) underwent SCS, because the recurrent site was
expected to be limited to a solitary aortic lymph node by CT. The
other two patients had PS 3 at surgery. One patient with three
metastatic brain tumours underwent emergent brain surgery
followed by g-knife radiosurgery to one residual tumour (Kawana
et al, 1997), and one patient underwent ileocaecal resection
because of acute bowel obstruction. Before the treatment, informed
consent was obtained from all of the patients.
Chemotherapy
Of 44 patients, 21 (47.7%) received chemotherapy before SCS and
all of 44 patients were treated with chemotherapy after SCS. In all,
one to eight (median: 2) cycles of presurgical chemotherapy were
performed in eight of 13 (61.5%) patients with DFI o12 months
and 13 of 31 (41.9%) patients with DFI 412 months. In total, 44
patients received two to nine (median: 4) cycles of postsurgical
chemotherapy.
In all, two to four cycles of presurgical chemotherapy were
generally administered until beneficial response (partial or minor
response) was observed. In two patients, second-line chemother-
apy showed no beneficial response, and SCS was performed after
successful third-line chemotherapy (seven and eight cycles in
total). One patient received only a cycle of presurgical chemother-
apy, because SCS could not be scheduled immediately after
diagnosis of recurrence.
The number of postsurgical chemotherapy given was deter-
mined by SCS outcome and response to chemotherapy, evaluated
by CT scan and serum level of CA125. Generally, three to four
cycles of chemotherapy were planned for patients with no residual
tumour and five to six cycles of chemotherapy were planned for
patients with any residual disease. In principle, we gave at least two
cycles of chemotherapy after the serum level of CA125 was
normalised. Thus, three patients were treated with more than six
cycles of chemotherapy after SCS. On the contrary, chemotherapy
was discontinued before accomplishment of the planned cycles in
five patients because rapid disease progression or severe adverse
effects were observed during the planned cycles.
In presurgical and postsurgical chemotherapies, a platinum-
based combination, CAP, EP or TJ, was used. The CAP regimen
consisted of 600mgm
 2 of cyclophosphamide, 30mgm
 2 of
doxorubicin and 50–75mgm
 2 of cisplatin. The EP regimen
consisted of 80mgm
 2 of etoposide during days 1–5 and
75mgm
 2 of cisplatin. Paclitaxel was introduced in Japan in
1998 and, thereafter, a TJ regimen consisting of paclitaxel
(175mgm
 2 over 3-h infusion) and AUC 5 of carboplatin was
used as second-line chemotherapy.
Statistical methods
Survival was measured from the day of starting treatment for
recurrence, that is, the day of starting presurgical chemotherapy or
the day of performing SCS. The survival curves were determined
by the Kaplan–Meier product limit method (Kaplan and Meier,
1958). Factors influencing survival were analysed using the log-
rank test (univariate) and Cox’s proportional-hazards regression
analysis (multivariate). These analyses were performed using a
JMP program (SAS Institute Inc., USA). Contingency table analysis
was performed using the w
2 test or w
2 test for trend.
RESULTS
Patient characteristics
The number of patients was three in stage I, two in stage II, 36 in
stage III and three in stage IV according to the International
Federation of Gynecology and Obstetrics (FIGO). Histology was
serous type in 35, clear-cell type in three, endometrioid type in
three, transitional cell type in two and mixed epithelial type in one.
Median DFI was 18.5 months with a range of 5–58 months: one
patient (2.3%) had 5 months, 12 (27.3%) had 6–12 months and 31
(70.5%) had 412 months. Median age at recurrence was 52 years
with a range of 37–74 years. Median follow-up period of patients,
excluding those who died, was 60 months with a range of 17–199
months from the initiation of treatment for recurrence.
Surgery
Our attempt to perform SCS resulted in exploratory laparotomy in
four patients (9.1%) due to the presence of unexpected extensive
peritoneal tumours. Various debulking surgeries classified into
four categories such as (1) gastrointestinal resection, (2) resection
of other organs, (3) lymph node dissection and (4) other tumour
debulking was performed with maximum efforts in the remaining
40 patients (90.9%). Among these patients, gastrointestinal
resection (category 1) was required in 11 patients (25.0%), large
bowel resection in nine patients (20.5%), small bowel resection in
three patients (6.8%), partial gastrectomy in one patient and
ileocaecal resection in one patient (2.3%), and one of the patients
(2.3%) underwent sigmoid colostomy. Three patients had category
1 surgeries at two sites. Resection of other organs (category 2) was
required in six patients (13.6%), splenectomy in three patients
(6.8%), distal pancreatectomy in two patients (4.5%), partial liver
resection in one patient, hysterectomy in one patient and brain
tumour resection in one patient (2.3%). Two patients had category
2 surgeries at two sites. Regional or distant lymph node dissection
(category 3) was performed in 12 patients (27.3%). Five patients
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s(11.4%) underwent systematic aortic lymphadenectomy and one
(2.3%) underwent both systematic pelvic and aortic lymphade-
nectomies. Selective dissections of the following lymph nodes were
performed in six patients: aortic nodes in one patient, pelvic nodes
in one patient, axillary nodes in one patient, portal nodes in one
patient, inguinal nodes in one patient and mesenteric nodes in one
patient (2.3%). Other tumour debulking (category 4) including
removal of tumours in the remnant omentum, the diaphragmatic
muscles and vaginal stump, and tumours on the visceral or parietal
peritoneum including the under surface of the diaphragm, was
performed in 22 patients (50.0%); omentectomy in seven patients;
partial full-thickness diaphragm resection in one patient; resection
of tumours around the vaginal stump in four patients (9.1%);
peritoneum resection of disseminated tumours on the under
surface of the diaphragm; and other peritoneal surfaces in 16
patients (36.4%). Six patients were counted twice because they
underwent two types of category 4 surgeries. In all, 10 patients
underwent two or three out of the above four categories of
debulking surgery. No patients died within a month following SCS.
Cytoreductive outcome and survival of patients
Among a total of 44 patients, complete resection of visible tumours
was achieved in 26 patients (59.1%), largest residual tumours
o1cm in diameter were left in 11 patients (25.0%) and largest
residual tumours X1cm in diameter were left in seven patients
(15.9%). The median survival and 5-year survival of all patients
who underwent cytoreductive surgery were 32 months and 33.2%
(Figure 1), whereas the median survival and 5-year survival of 26
patients who had recurrence after complete remission achieved by
primary treatment and did not undergo the surgery were 11
months and 3.9%. Figure 2 shows the survival of patients after the
initiation of treatment for recurrence according to the outcome of
SCS (SCS outcome). The median survival and 5-year survival after
recurrence of the patients with largest residual tumours 0, o1 and
X1cm were 52 months and 47.6%, 23 months and 18.2% and 20
months and 0%, respectively (P¼0.0007, log rank). The overall
survival of patients with no residual tumour was much better than
that of patients with residual tumours (22 months in median
survival and 12.0% in 5-year survival, figure not shown) with
statistical significance (P¼0.0019). There was no statistical
difference in overall survival between patients with residual
tumours o1 and X1cm(P¼0.1314).
Factors influencing survival in univariate analyses
Factors influencing overall survival after recurrence were analysed
using univariate analyses. Factors analysed and the results of
univariate analyses are listed in Tables 1 and 2. As for prognostic
factors determined during primary therapy, univariate analyses
revealed that peritoneal tumour spread (P¼0.039), FIGO stage
(P¼0.045) and aortic lymph node metastasis (P¼0.009) were
significantly associated with overall survival after recurrence.
Regarding prognostic factors determined at recurrence, univariate
analyses revealed that DFI (P¼0.002), presence of liver metastasis
(P¼0.005), number of recurrent tumours (P¼0.007), size of
maximum tumour (Po0.001) and SCS outcome (P¼0.002) had
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Figure 2 Outcome of SCS and survival. Survival of the patients with
largest residual tumours 0, o1 and X1cm is shown in solid black, solid
grey and dotted black line, respectively. The difference of survival is
statistically significant (P¼0.0007, log rank). There is no statistical difference
in survival between patients with residual tumours o1 and X1cm
(P¼0.1314, log rank).





Localised to the pelvis 10 NA
Extended beyond the pelvis 34 29 0.039
Stage
I/II 5 NA
III/IV 39 29 0.045
Aortic lymph node metastases
Absent 25 64
Present 14 27
Not assessed 5 25 0.009
Pelvic lymph node metastases
Absent 20 47
Present 21 32
Not assessed 3 25 0.126
Systematic lymphadenectomy
Not performed 3 25
Pelvic only 7 29
Pelvic and aortic 34 33 0.296
Histology
Serous 35 37
Others 9 23 0.197
Residual tumour at PCS
03 4 3 2
Any 10 40 0.961
PCS¼primary cytoreductive surgery; NA¼not applicable.
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sFactors influencing survival in multivariate analysis
To determine patient selection for the surgery, we performed
multivariate analysis using statistically significant prognostic
factors in univariate analyses. Out of eight significant factors,
SCS outcome was omitted in the multivariate analysis because SCS
outcome is not yet known on considering indications for the
surgery, although SCS outcome had a statistically significant
correlation with the number of recurrent tumours (Po0.001, w
2
test). The multivariate analysis using the remaining seven factors
revealed that four factors determined at recurrence, specifically
DFI, presence of liver metastasis, number of recurrent tumour and
size of maximum tumour, were independently and significantly
associated with survival after recurrence (Table 3). Additionally,
the multivariate analysis using only these four factors confirmed
that all four factors were independently and significantly
associated with survival after recurrence. The relative risk (95%
confidence interval) was 0.37 (0.20–0.68) for DFI 412 months,
0.23 (0.10–0.65) for absence of liver metastasis, 0.26 (0.12–0.48)
for a solitary tumour and 0.20 (0.09–0.42) for size of maximum
tumour o6cm.
Grouping of patients determined by the number of
favourable prognostic factors
According to the number of favourable statuses among the above-
mentioned four prognostic factors, that is, DFI 412 months, no
liver metastasis, solitary tumour and tumour size o6cm, patients
were divided into four groups as follows: patients with all four
favourable factors (Group 4, n¼10), patients with three favourable
factors (Group 3, n¼21), patients with two favourable factors
(Group 2, n¼11) and patients with only one favourable factor
(Group 1, n¼2). There were no patients with zero favourable
factors. Complete resection of visible tumours was achieved in
100% (10 of 10), 62% (13 of 21), 18% (two of 11) and 50% (one of
two) of patients in Group 4, Group 3, Group 2 and Group 1,
respectively. Apparently, a higher rate of complete surgical
resection was achieved in patients with a larger number of
favourable factors, and the distribution was statistically significant
by contingency table analysis (Po0.001, w
2 test for trend). The 5-
year survival of Group 4 was 88.9% and median survival was not
reached. The 5-year survivals and median survivals of Group 3,
Group 2 and Group 1 were 26.0, 0 and 0%, and 37, 20 and 10
months, respectively (figure not shown). The differences of overall
survival were also statistically significant among the four groups
(Po0.001, log rank) and between them (e.g. Po0.007 in Group 1
vs Group 2, Po0.001 in Group 2 vs Group 3 and Po0.001 in Group
Table 2 Univariate analyses for variables at recurrence
Variables Number Median survival (months) P-value
Age at recurrence (years)
o50 17 29
X50 27 40 0.860
Disease-free interval (months)
X12 31 47
o12 13 23 0.002
Intraperitoneal tumour
Absent 12 64
Present 32 27 0.117
Pelvic or aortic lymph node metastases
Absent 34 32
Present 10 37 0.419
Distant metastasis
Absent 38 32
Present 6 40 0.496
Liver metastasis
Absent 42 33
Present 2 20 0.005
No. of recurrent tumours
Solitary 16 64
Multiple 28 27 0.007
Size of maximum tumour (cm)
o63 8 4 0
X66 1 4 o0.001
Massive ascites (4500ml)
Absent 41 33
Present 3 32 0.318
PS
0–2 42 29
3 2 42 0.746
Presurgical chemotherapy
Not done 23 33
Done 21 29 0.677
Bowel resection
Not done 33 33
Done 11 27 0.650
Residual tumour at SCS
02 6 5 2
Any 18 22 0.002
PS¼performance status; SCS¼secondary cytoreductive surgery.
Table 3 Multivariate analysis using the seven prognostic variables in the
univariate analyses
Multivariate analysis
Variables Risk ratio (95% CI) P-value
Peritoneal tumour spread at PCS
Localised to the pelvis 1.00
Extended beyond the pelvis 0.80 (0.42–1.76) 0.540
Stage
I/II 1.00
III/IV 0.90 (0.22–5.60) 0.893
Aortic lymph node metastases at PCS
Absent 1.00
Present 1.23 (0.56–2.64)
Not assessed 1.78 (0.61–5.33) 0.088
Disease-free interval (months)
X12 1.00
o12 2.45 (1.11–5.39) 0.027
Liver metastasis
Absent 1.00
Present 4.00 (1.40–10.03) 0.013
No. of recurrent tumours
Solitary 1.00
Multiple 3.73 (1.79–9.58) o0.001
Size of maximum tumour (cm)
o6 1.00
X6 7.43 (3.12–18.92) o0.001
PCS¼primary cytoreductive surgery.
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s3 vs Group 4, log rank). Figure 3 shows the combined survival of
Group 4 and Group 3 and that of Group 2 and Group 1. Patients
with three or all four favourable factors (Group 3/4) (n¼31) had
significantly better survival compared with those with less than
three favourable factors (Group 1/2) (n¼13) (median and 5-year
survival; 47 months and 45.9% vs 20 months and 0%, Po0.001).
Survival of patients determined by the number of
favourable prognostic factors and SCS outcome
Patients with three or all four favourable prognostic factors (Group
3/4) had better survival when complete surgical resection was
achieved at the time of SCS (n¼23) (64 months in median
survival, 53.8% in 5-year survival). However, even when SCS left
residual tumours, survival of the Group 3/4 patients (n¼8) was
fairly good (40 months in median survival, 25% in 5-year survival).
On the other hand, Group 1/2 patients had poorer survival both in
completely resected cases (n¼3) and in incompletely resected
cases (n¼10) (23 and 18 months in median survival, and 0 and 0%
in 5-year survival) (Figure 4).
DISCUSSION
We achieved surgical removal of all visible tumours in 59.1% of
patients at the time of SCS. Residual tumours o1o rX1cm in
diameter were present in 25.0 and 15.9%, respectively. In line with
previous reports, removal of all visible tumours at SCS contributed
to long-term survival (Figure 2). The rate of complete resection
(59.1%) in our series was a little lower than the rates reported by
Eisenkop et al (2000), Landoni et al (1998) and Cormio et al
(1999). However, in Landoni’s study, the subjects were restricted to
those patients who were sensitive to first-line chemotherapy and
chemotherapy before SCS. Cormio et al also restricted the subjects
to patients with apparently isolated and resectable tumours and
without ascites. Our criteria for patient selection were similar to
those of Eisenkop et al, and their subjects were patients with DFI
46 months and without liver metastases. They achieved an 82%
complete resection rate by using argon beam laser to remove
disseminated cancer foci and reported 44 months in median
survival and approximately 35% in 5-year survival in the
completely resected cases. In our experience, median survival
and 5-year survival in completely resected cases were 52 months
and 47.6%, respectively, being much better than previous reports.
Our rate of optimal cytoreduction, 84.1% (if defined as residual
tumour o1cm), was similar to the rate of complete resection in
Eisenkop’s report. In our series, optimally resected cases had 40
months in median survival and 38.6% in 5-year survival (figure not
shown), in keeping with the survival of completely resected cases
in Eisenkop’s study. These findings suggest that the debulking
efforts performed at SCS in our cases are comparable to those of
previous reports.
Univariate analyses revealed that three factors during primary
treatment (peritoneal spread, aortic lymph node metastasis, FIGO
stage) and five factors at recurrence (DFI, liver metastasis, number
of tumours, size of maximum tumour, SCS outcome) were
significantly related to overall survival after recurrence. In the
multivariate analysis excluding SCS outcome, the significance of all
the three factors during primary treatment disappeared. Four
factors determined at recurrence, that is, DFI, presence of liver
metastasis, number of tumours and size of maximum tumour,
were revealed to be independent prognostic factors.
DFI is the most important prognostic factor after recurrence, as
described in many previous reports. In most studies, the cutoff
period of DFI was set to 12 months. Two cutoff periods were set in
Eisenkop’s study (Eisenkop et al, 2000) (12 and 36 months) and in
Tay’s study (Tay et al, 2002) (12 and 24 months), and patients were
divided into three groups. Although we also analysed our patients
with DFI 412 months using cutoff periods such as 24 and 36
months, there were no significant differences between patients
with and without DFI 424 or 36 months (data not shown).
Recently, Zang et al (2004) performed SCS even in patients with
DFI of 3 months and reported negative influence of DFI on overall
survival. However, their follow-up period was only 16 months.
This might be too short to detect a statistical difference.
Size of maximum tumour was also identified by Eisenkop et al
(2000) as an independent prognostic factor. Eisenkop et al used
10cm as the cutoff size, whereas we used 6cm. The difference may
be due to our earlier detection of recurrent tumours by using
ultrasonography or CT scan within a 3-month interval. In our
cases, there were only two patients in whom maximum tumour
size exceeded 10cm in diameter. At all events, tumour size seems
to be an important factor reflecting biological aggressiveness of
recurrent tumours.
The number of recurrent tumours has not been previously
highlighted as a prognostic determinant. One reason is that some
studies restricted the subjects for SCS to patients with isolated
tumours or a solitary tumour (Cormio et al, 1999; Munkarah et al,
2001; Scarabelli et al, 2001). Another possible reason is that














Figure 3 Comparison in survival between patients having one or two
favourable prognostic factors (Group 1/2) and three or four favourable
factors (Group 3/4). Survival of patients in Group 3/4 and Group 1/2 is
shown as a solid black or solid grey line, respectively. Patients in Group 3/4
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Group 3/4  and residual =0 (n=23)
Group 3/4  and residual >0 (n=8)
Group 1/2  and residual =0 (n=3)
Group 1/2  and residual >0 (n=10)
Figure 4 Survival in relation to SCS outcome and number of favourable
prognostic factors. Survival of patients in Group 3/4 are shown as solid lines.
Solid black line and solid grey line show the survival of patients with no
residual tumour and residual tumour at SCS, respectively. Survival of
patients in Group 1/2 are shown as dotted lines. Dotted black line and
dotted grey line show the survival of patients with no residual tumour and
any residual tumour at SCS, respectively.
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snumber of recurrent tumours as a factor influencing survival,
although they pointed out that this factor may influence SCS
outcome. In concordance with our results, Zang et al (2004)
reported that the number of recurrent tumours influenced both
overall survival and SCS outcome.
The current study revealed that liver metastasis is another
important prognostic determinant. Vaccarello et al (1995)
examined the relationship between site of recurrence and survival,
and reported that liver metastasis had a negative influence on
survival. In most studies, patients with liver metastasis were
excluded from subjects for SCS. In our series, two patients with
solitary liver metastasis were included: one patient underwent
hepatic resection and the other patient did not undergo hepatic
resection because of the presence of unresectable metastatic portal
lymph nodes. They did not achieve good survival (20 and 14
months, respectively).
From the results of the multivariate analysis, we propose the
following criteria for patient selection for SCS. Patients with
recurrent ovarian cancer should be considered as ideal candidates
for SCS when they have three or all of the following four factors at
recurrence: (1) DFI 412 months, (2) no liver metastasis, (3) a
solitary tumour and (4) tumour size o6cm. Considering our
original patient selection, we should propose exclusion criteria
including (1) age at recurrence X75 years, (2) PS 3 or 4 just before
SCS and (3) progressive disease during presurgical chemotherapy,
if undertaken. Although we used intraoperative findings for the
number and size of tumours, size of maximum tumour was
consistent between intraoperative findings and imaging in
available cases. Therefore, we can accurately evaluate all these
factors, except the number of tumours, before SCS. As for the
number of tumours, ultrasonography or CT scan before SCS
cannot always identify multiple peritoneal disseminated tumours.
When the patient meets the criteria for SCS preoperatively, it is
recommended to decide whether SCS should be accomplished after
reconfirming the criteria at the time of laparotomy.
In the previous studies, several prognostic factors were shown to
have significant correlation with overall survival of the patients.
However, these factors were obtained from SCS in selected patients
in most of the previous studies. In addition, how to use several
significant prognostic factors to select good candidates for SCS was
not fully analysed. To our knowledge, generally accepted or
recommended selection criteria are ‘patients with longer DFI’
(Bristow et al, 1996; Roberts, 1996; Rose, 2000; Sijmons and Heintz,
2000). Thus, it was sometimes difficult to decide whether or not
SCS should be performed in patients who have some favourable
factors and a few unfavourable factors. We believe that our
selection criteria for SCS should be helpful in deciding whether
SCS should be performed.
In conclusion, our data suggest that patients with three
or all four of the above-mentioned favourable factors are
ideal candidates for SCS, and that the final decision should be
made at laparotomy in borderline cases. It seems that SCS
has a large impact on survival of patients with recurrent ovarian
cancer when the patients are selected by the new criteria
(47 months in median survival and 45.9% in 5-year survival).
However, these patients were likely to have good sensitivity
to chemotherapy, because they had DFI 46 months. In a recent
trial of recurrent ovarian cancer with DFI 46 months, patients
who received platinum-based chemotherapy with or without
paclitaxel had a favourable prognosis: 29 and 24 months in
median survival and around 20% in 5-year survival, respec-
tively (Parmar et al, 2003). Although patients undergoing
SCS using the new criteria of patient selection seem to have
much better survival than patients receiving chemotherapy
alone, our study was retrospective and noncomparative, and
our data were based on a relatively small number of strictly
selected patients. To provide solid evidence for the therapeutic
benefit of SCS and to find better selection criteria for the
surgery, further studies including randomised controlled
studies are required.
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